Irritable%20bowel%20syndrome News

News

Rifaximin helps improve symptoms of IBS with diarrhoea

20230321060000

Treatment with rifaximin appears to produce significant reductions in multiple, concurrent symptoms of irritable bowel syndrome (IBS) with diarrhoea, according to a study that uses a novel tri-symptom endpoint.

Mesalamine shows modest benefit in IBS

20230306060000

Treatment with mesalamine may only have modest efficacy for the global symptoms of irritable bowel syndrome (IBS), specifically IBS that causes increased diarrhoea, according to the results of a meta-analysis. However, the quality of evidence appears to be low.

Acupuncture safe, feasible in irritable bowel syndrome

20230130060000

Acupuncture appears to yield significant improvements in irritable bowel syndrome with diarrhoea (IBS-D), a study has found.

Transcutaneous electrical acustimulation effective in IBS with constipation

20220930130000

Patients with irritable bowel syndrome (IBS) and constipation (IBS-C) can improve their symptoms by undergoing transcutaneous electrical acustimulation (TEA), suggests a study. TEA speeds up colon transit and reduces rectal sensation, which is potentially mediated by using the autonomic mechanisms.

Faecal microbiota transplant offers no relief for IBS

Tristan Manalac, 20220926090000

Patients with irritable bowel syndrome (IBS) derive no clear benefit from faecal microbiota transplant (FMT), according to a recent study.

Having regular meals helps prevent IBS in adults

20220921130000

Individuals who observe a regular meal pattern are less likely to have irritable bowel syndrome (IBS), IBS-mixed, and the syndrome severity, a study has shown. Meal regularity is also associated with lower IBS prevalence in women and in those with normal weight.

Low-FODMAP diet trumps medication for IBS

Tristan Manalac, 20220711090000

In primary care patients with irritable bowel syndrome (IBS), keeping a diet low in fermentable oligo-, di-, and monosaccharides and polyols (FODMAP), as guided by a smartphone app, yields better symptom relief than using a spasmolytic agent, according to a recent trial.

Does IBS elevate long-term risk of cancer?

Stephen Padilla, 20220607120000

People with irritable bowel syndrome (IBS) are not at increased overall risk of cancer relative to the general population, reveals a study. On the contrary, those with IBS appear to have a lower risk of incident colorectal cancer (CRC) and cancer-specific mortality.

$Group CBT with interoceptive exposure safe, effective for drug-refractory IBS$

Group CBT with interoceptive exposure safe, effective for drug-refractory IBS

20220418130000

Group cognitive behavioural therapy (GCBT) with interoceptive exposure (IE) is not only safe and effective but also an efficient treatment option for individuals with drug-refractory irritable bowel syndrome (IBS), according to a Japan study.

Medication risks an acceptable trade-off for cure of IBS symptoms

20220307180000

Patients with irritable bowel syndrome (IBS) are willing to take on significant medication risks in exchange for a permanent cure of their symptoms, a study has found.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).

Product Highlight - Ravida

13 Sep 2022

Ravidasvir 200 mg tab

Product Highlight - Salofalk

12 Mar 2021

SALOFALK – Mesalazine 1.5 g PR granules